Business Context and Reporting Period
Company: OSR Holdings, Inc. (f/k/a Bellevue Life Sciences Acquisition Corp.)
Filing Date: February 14, 2025
Event: Completion of Business Combination with OSR Holdings Co., Ltd. (Korea).
Status: The Company ceased to be a shell company upon closing. Common stock (OSRH) and warrants (OSRHW) commenced trading on Nasdaq on February 18, 2025.
Key Financial Metrics and Capital Structure
Note: This 8-K filing reports the closing of a transaction and incorporates financial statements by reference. Specific revenue, profit, and cash flow figures are not detailed in this text but are located in Exhibits 99.1 through 99.4.
- Share Issuance: 16,282,047 shares of Company Common Stock issued to Participating Stockholders in exchange for 1,256,085 shares of OSR Common Stock.
- Ownership Structure:
- Company owns approximately 67% of outstanding OSR Common Stock.
- Non-Participating Stockholders hold approximately 22% of OSR Common Stock (subject to Put/Call rights).
- Approximately 11% of OSR Common Stock remains with holders who did not sign a Joinder (no conversion rights).
- Outstanding Securities (Post-Closing):
- Common Stock: 19,276,978 shares.
- Warrants: 7,330,000 warrants outstanding.
- Major Beneficial Owners:
- Kuk Hyoun Hwang: 67.8% (13,069,104 shares).
- BCM Europe AG: 44.7% (8,612,634 shares).
- Bellevue Capital Management LLC: 16.2% (3,123,970 shares).
Material Changes and Transaction Terms
- Share Exchange: Participating Stockholders exchanged OSR Series A common stock for Company Common Stock.
- Put and Call Rights: Non-Participating Stockholders (22% stake) have rights to force the Company to purchase their shares (Put Right) or the Company to force a sale (Call Right).
- Trigger Date: Earlier of January 1, 2026, or a change in control notification.
- Expiration: 120 days after the Trigger Date.
- Settlement: Fixed exchange ratio; no cash settlement option.
- Lock-Up Agreements:
- Bellevue Capital Management LLC and BCM Europe AG: Restricted from selling 70%-100% of shares for 36 months.
- Sung Jae Yu and Sung Hoon Chung: Restricted until January 1, 2026.
- Management Changes:
- Kuk Hyoun Hwang appointed President and CEO.
- Gihyoun Bang appointed CFO.
- David J. Yoo resigned as CFO of the predecessor entity (BLAC).
Guidance, Outlook, and Risks
Dividend Policy: The Board intends to retain all earnings for operations and does not anticipate declaring dividends in the foreseeable future.
Forward-Looking Risks: The filing highlights significant uncertainties, including:
- Ability to achieve or sustain profitability.
- Failure to realize anticipated benefits of the Business Combination.
- Risks related to maintaining Nasdaq listing.
- Regulatory changes and litigation outcomes.
- Integration challenges and market acceptance of the business model.
Financial Data Reference: Detailed MD&A, audited financial statements (2022-2023), and unaudited pro forma combined financial information are incorporated by reference in Exhibits 99.1 through 99.4.
Investor Verification Checklist
- Pro Forma Financials: Review Exhibit 99.4 for unaudited pro forma condensed combined financial information to understand the combined entity's financial position.
- Put/Call Liability: Assess the potential cash or share dilution impact of the Put/Call rights held by the 22% Non-Participating Stockholders, exercisable after the Trigger Date.
- Lock-Up Expirations: Monitor the 36-month lock-up for major institutional holders (BCM/BCME) and the January 1, 2026 expiration for key individuals.
- Minority Stake: Verify the status of the 11% of OSR stock held by non-signatories, which remains outside the Company's control and lacks conversion rights.
- Profitability Path: Examine the MD&A (Exhibit 99.1) for specific strategies to achieve profitability, as the filing explicitly lists this as a key risk.